Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases

Wait 5 sec.

Merida's antibody-engineering platform is designed to enable precise, durable removal of disease-causing antibodies, while preserving normal immune function Initial Phase 1 data show MER511 achieved robust reductions in pathogenic thyroid-stimulating antibodies with a favorable initial...